Important Investor Alert: Levi & Korsinsky, LLP Announces Class Action Lawsuit Against Novo Nordisk A/S
NEW YORK, Feb. 10, 2025 – Levi & Korsinsky, LLP announces that a class action securities lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of shareholders of Novo Nordisk A/S (“Novo” or the “Company”) (NYSE: NVO).
The complaint alleges that Novo and certain of its top executives violated the Securities Exchange Act of 1934 by making false and/or misleading statements and/or failing to disclose material information to the investing public.
Background
Novo is a Danish pharmaceutical company that develops and manufactures medicines for diabetes and other serious chronic diseases. The Company is headquartered in Bagsværd, Denmark, and has approximately 44,000 employees worldwide.
Allegations
The complaint alleges that Novo and its executives made false and/or misleading statements and/or failed to disclose material information to investors regarding the Company’s financial results and business operations, particularly with respect to:
- The Company’s sales and marketing practices for its diabetes drug, Victoza;
- The Company’s financial reporting and accounting practices;
- The Company’s internal controls and compliance policies;
The complaint further alleges that these misrepresentations and omissions artificially inflated the price of Novo’s common stock.
Impact on Investors
If you purchased or otherwise acquired Novo securities between March 1, 2020 and January 31, 2025 and suffered a loss, you may be entitled to recover your loss. To get more information, go to:
Impact on the World
The outcome of this lawsuit could have significant implications for the pharmaceutical industry as a whole, as it raises questions about the transparency and accountability of drug companies’ sales and marketing practices, financial reporting, and internal controls. It also highlights the importance of shareholder oversight and the role of securities class action lawsuits in holding corporations accountable for their actions.
Conclusion
The securities lawyers at Levi & Korsinsky are committed to recovering losses for investors harmed by corporate misconduct. If you purchased or otherwise acquired Novo securities between March 1, 2020 and January 31, 2025, please contact us for a free consultation. Our team of attorneys will evaluate your case and provide you with the information you need to decide whether to participate in the action.
Levi & Korsinsky, LLP has extensive experience in prosecuting securities class actions and extensive expertise in actions involving pharmaceutical companies. For more information, please feel free to call us at 212-363-7500 or contact us via email at [email protected].
